These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17956231)

  • 1. Cross-link breakers as a new therapeutic approach to cardiovascular disease.
    Susic D
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):853-6. PubMed ID: 17956231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.
    Bakris GL; Bank AJ; Kass DA; Neutel JM; Preston RA; Oparil S
    Am J Hypertens; 2004 Dec; 17(12 Pt 2):23S-30S. PubMed ID: 15607432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications.
    Hartog JW; Voors AA; Bakker SJ; Smit AJ; van Veldhuisen DJ
    Eur J Heart Fail; 2007 Dec; 9(12):1146-55. PubMed ID: 18023248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics, formation, and pathophysiology of glucosepane: a major protein cross-link.
    Sjöberg JS; Bulterijs S
    Rejuvenation Res; 2009 Apr; 12(2):137-48. PubMed ID: 19415980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis.
    Meerwaldt R; Zeebregts CJ; Navis G; Hillebrands JL; Lefrandt JD; Smit AJ
    Am J Kidney Dis; 2009 Jan; 53(1):138-50. PubMed ID: 19036487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of arterial stiffening: role of glycation - a mini-review.
    Sell DR; Monnier VM
    Gerontology; 2012; 58(3):227-37. PubMed ID: 22222677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAGE: a new pleiotropic antagonistic gene?
    Simm A; Bartling B; Silber RE
    Ann N Y Acad Sci; 2004 Jun; 1019():228-31. PubMed ID: 15247020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.
    Yamagishi S; Nakamura K; Matsui T; Ueda S; Noda Y; Imaizumi T
    Cardiovasc Ther; 2008; 26(1):50-8. PubMed ID: 18466420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases.
    Reddy VP; Beyaz A
    Drug Discov Today; 2006 Jul; 11(13-14):646-54. PubMed ID: 16793534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth factors, AGEing, and the diabetes link in Alzheimer's disease.
    Loy CT; Twigg SM
    J Alzheimers Dis; 2009; 16(4):823-31. PubMed ID: 19387115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-linking of the extracellular matrix by the maillard reaction in aging and diabetes: an update on "a puzzle nearing resolution".
    Monnier VM; Mustata GT; Biemel KL; Reihl O; Lederer MO; Zhenyu D; Sell DR
    Ann N Y Acad Sci; 2005 Jun; 1043():533-44. PubMed ID: 16037276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes.
    Peyroux J; Sternberg M
    Pathol Biol (Paris); 2006 Sep; 54(7):405-19. PubMed ID: 16978799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?
    Kanková K
    Proc Nutr Soc; 2008 Feb; 67(1):60-74. PubMed ID: 18234133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosslink breakers: a new approach to cardiovascular therapy.
    Susic D; Varagic J; Ahn J; Frohlich ED
    Curr Opin Cardiol; 2004 Jul; 19(4):336-40. PubMed ID: 15218393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced glycation end-products diminish tendon collagen fiber sliding.
    Li Y; Fessel G; Georgiadis M; Snedeker JG
    Matrix Biol; 2013 Apr; 32(3-4):169-77. PubMed ID: 23348249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics of arterial structure and function: towards new biomarkers for aortic stiffness?
    Yasmin ; O'Shaughnessy KM
    Clin Sci (Lond); 2008 Jun; 114(11):661-77. PubMed ID: 18442360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ageing of the conduit arteries.
    Greenwald SE
    J Pathol; 2007 Jan; 211(2):157-72. PubMed ID: 17200940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers.
    Yamagishi S; Matsui T; Nakamura K
    Med Hypotheses; 2008 Aug; 71(2):259-61. PubMed ID: 18448262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced glycation end products and diabetic foot disease.
    Huijberts MS; Schaper NC; Schalkwijk CG
    Diabetes Metab Res Rev; 2008; 24 Suppl 1():S19-24. PubMed ID: 18442180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced glycation end-product cross-link breakers. A novel therapeutic pathway for cardiovascular disease.
    Hollenberg NK
    Am J Hypertens; 2004 Dec; 17(12 Pt 2):21S-22S. PubMed ID: 15607431
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.